Overcoming MCL-1-driven adaptive resistance to targeted therapies

Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications 2020-01, Vol.11 (1), p.531-531, Article 531
1. Verfasser:	Wood, Kris C.
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/106 59 631/67/1059/602 64 64/60 692/4028/67/1059/2326 82/1 96 96/2 Apoptosis Bioavailability Cancer Comment Cytochrome Drug dosages Drug Resistance, Neoplasm Humanities and Social Sciences Humans MAP Kinase Signaling System Mcl-1 protein Medical research Melanoma multidisciplinary Myeloid Cell Leukemia Sequence 1 Protein Proteins Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins c-bcl-2 Science Science (multidisciplinary) Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.
ISSN:	2041-1723 2041-1723
DOI:	10.1038/s41467-020-14392-z